Department of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Tissue Eng Regen Med. 2023 Jul;20(4):523-538. doi: 10.1007/s13770-023-00522-3. Epub 2023 Mar 9.
During high-throughput drug screening, in vitro models are fabricated and the effects of therapeutics on the models evaluated in high throughput-for example, with automated liquid handling systems and microplate reader-based high-throughput screening (HTS) assays. The most frequently-used model systems for HTS, 2D models, do not adequately model the in vivo 3D microenvironment-an important aspect of which is the extracellular matrix-and therefore, 2D models may not be appropriate for drug screening. Instead, tissue-engineered 3D models with extracellular matrix-mimicking components are destined to become the preferred in vitro systems for HTS. However, for 3D models, such as 3D cell-laden hydrogels and scaffolds, cell sheets, and spheroids as well as 3D microfluidic and organ-on-a-chip systems, to replace 2D models in HTS, they must be compatible with high-throughput fabrication schemes and evaluation methods. In this review, we summarize HTS in 2D models and discuss recent studies that have successfully demonstrated HTS-compatible 3D models of high-impact diseases, such as cancers or cardiovascular diseases.
在高通量药物筛选过程中,会构建体外模型,并在高通量水平上评估治疗方法对这些模型的影响,例如采用自动化液体处理系统和微孔板读板机进行高通量筛选(HTS)实验。最常用于 HTS 的模型系统二维模型不能充分模拟体内 3D 微环境,而 3D 微环境的一个重要方面是细胞外基质,因此,二维模型可能不适合用于药物筛选。相反,具有细胞外基质模拟成分的组织工程 3D 模型注定将成为 HTS 的首选体外系统。然而,对于 3D 模型,例如 3D 细胞负载水凝胶和支架、细胞片和球体以及 3D 微流控和芯片上器官系统,要想在 HTS 中取代二维模型,它们必须与高通量制造方案和评估方法兼容。在这篇综述中,我们总结了二维模型中的 HTS,并讨论了最近成功展示了具有高影响力疾病(如癌症或心血管疾病)的高通量筛选兼容 3D 模型的研究。